ReviewCells2026
From Yeast Probiotics to Postbiotics: A Continuum Model and Yeast-Specific Functional Perspective.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing interest in probiotics and postbiotics has expanded research beyond living microorganisms and highlighted the functional importance of microbial cells, metabolites, and structural components. However, current conceptual frameworks still primarily focus on bacteria, while yeasts, despite their industrial, nutritional, and clinical importance, remain underrepresented. Owing to their eukaryotic organization, complex cell wall architecture, specialized secretory pathways, and ability to produce diverse bioactive molecules, yeasts exhibit functional properties that are distinct from those described for bacterial probiotics and postbiotics. In this review, we examine the relationship between yeast probiotics and yeast-derived postbiotics and propose the concept of a yeast-biotic continuum, which describes biological functionality as a dynamic progression from living cells, through active metabolism and released bioactive factors, to inactivated cells and postbiotic preparations. In this approach, postbiotics are viewed not as static end products but as steps in a continuous biological process influenced by cell viability, environmental conditions, and interactions with the surrounding microbiota. We discuss major yeast-derived bioactive components, including β-glucans, mannoproteins, metabolites, peptides, and extracellular vesicles, together with their roles in immune modulation, epithelial barrier support, pathogen interference, and fungi-bacteria-host interactions. Finally, we highlight current challenges, emerging technologies, and future opportunities for yeast-derived biotics.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.